Contribute Try STAT+ Today

Rise and shine, everyone, another busy day is on the way. We can tell because once again, the shortest person dashed off to the local schoolhouse. Ring, ring, goes the bell. As for us, the coffee kettle is whistling away as we ready still more cups of stimulation. Our choice today is cinnamon swirl. Feel free to join us or, if you prefer, reach for a water bottle. Meanwhile, here are a few tidbits to help you move down the tracks. Hope you have a splendid day and, as always, please do keep in touch …

Drug makers and their trade groups shelled out millions of dollars to lobby Congress as it considered legislation aimed at reining in skyrocketing drug prices, The Hill writes, citing new lobbying disclosure reports. PhRMA — the trade group representing brand-name drug companies — spent $6.2 million on lobbying in the third quarter of 2019, which ran from July through the end of September. That was $240,000 more than it spent during the same time frame last year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.